Skip to content
Catalyst

vitamin D2What was measured

Measured, with no finding

344 endpoints

Show what was measuredHide what was measured
  • absolute change in serum 25(OH)D concentration from baseline, vitamin D2 versus vitamin D3, weighted mean difference, random effects

    decreases, WMD 15.23 nmol/L (95% CI 6.12, 24.34) favouring cholecalciferol over ergocalciferol, p = 0.001

    Not recorded as a finding: the comparison was against another active treatment

    With the use of a random-effects model, overall, there was a significantly greater effect in the raising of serum 25(OH)D concentrations over time for D3 supplementation than for D2 supplementation (mean difference: 15.23; 95% CI: 6.12, 24.34; P = 0.001).

    PMID 22552031 · one of two readings recorded this

  • absolute change in serum 25(OH)D from baseline (nmol/L), vitamin D2 versus vitamin D3, overall and by daily versus bolus dosing

    cholecalciferol minus ergocalciferol WMD 15.23 nmol/L (95% CI 6.12, 24.34), p = 0.001

    Not recorded as a finding: the comparison was against another active treatment

    Overall, the analysis showed that the greater absolute change in serum 25(OH)D from baseline favored the cholecalciferol intervention, with a weighted mean difference of 15.23 (95% CI: 6.12, 24.34; Z = 3.28; P = 0.001).

    PMID 22552031 · one of two readings recorded this

  • Change in serum 25(OH)D from baseline

    increases, p = 0.001

    the greater absolute change in serum 25(OH)D from baseline favored the cholecalciferol intervention, with a weighted mean difference of 15.23 (95% CI: 6.12, 24.34; Z = 3.28; P = 0.001)

    PMID 22552031 · one of two readings recorded this

  • Change in serum 25(OH)D from baseline

    increases, p = 0.0002

    Three of these studies had data available that showed that bolus doses favored cholecalciferol with a weighted mean difference of 34.10 (95% CI: 16.38, 51.83; Z = 3.77; P = 0.0002)

    PMID 22552031 · one of two readings recorded this

  • Change in serum 25(OH)D from baseline

    no effect, p = 0.1

    the result was nonsignificant with a weight mean difference of 4.83 (95% CI: −0.98, 10.64; Z = 1.63; P = 0.10)

    PMID 22552031 · one of two readings recorded this

  • Serum 25(OH)D concentration

    no effect, n = 68

    Holick et al, 2008; United States | 1) Placebo | 68 | 47 F | 11 wk | At the end of the intervention, there was no significant difference in 25(OH)D concentrations between vitamin D2 and D3 groups.

    PMID 22552031 · one of two readings recorded this

  • Serum 25(OH)D increase

    increases, n = 69

    Leventis and Kiely 2009; United Kingdom | Study 1: single intramuscular injection of 300,000 IU vitamin D2 | 69 | Study 1: 43 F and 7 M | 24 wk | Greater increases in serum 25(OH)D were achieved with vitamin D3 intervention

    PMID 22552031 · one of two readings recorded this

  • Serum 25(OH)D increase

    increases, p = 0.01, n = 70

    Glendenning et al, 2009; Australia | 1) Ergocalciferol 1000 IU/d | 70 | Sex | 3 mo | Vitamin D3 supplementation was associated with a 31% greater increase in concentrations of serum 25(OH)D than was vitamin D2 supplementation (P = 0.01).

    PMID 22552031 · one of two readings recorded this

  • Serum 25(OH)D increase

    increases, n = 19

    Tjellesen et al, 1986; Denmark | 1) 4000 IU vitamin D3 2) 4000 IU vitamin D2 | 19 | All F22–49 y | 8 wk | Vitamin D3 was linked to a greater increase in serum 25(OH)D compared with that in the vitamin D2 intervention group. No direct statistical comparison results were available.

    PMID 22552031 · one of two readings recorded this

  • Serum 25(OH)D increase

    increases, p = 0.03, n = 89

    Trang et al, 1998; Canada | 1) Untreated 2) 4000 IU vitamin D2 3) 4000 IU vitamin D3 | 89 | 48 F23 M18 Unknown38 ± 9 y | 14 d | Greater increase in serum 25(OH)D concentrations with vitamin D3 group than with vitamin D2 group (P = 0.03).

    PMID 22552031 · one of two readings recorded this

  • All-cause mortality

    decreases, p = 0.02

    Vitamin D decreased mortality in all 56 trials analysed together (5,920/47,472 (12.5%) vs 6,077/47,814 (12.7%); RR 0.97 (95% confidence interval (CI) 0.94 to 0.99); P = 0.02

    PMID 24414552 · one of two readings recorded this

  • All-cause mortality

    decreases, p = 0.002, n = 75927

    only vitamin D3 decreased mortality (4,153/37,817 (11.0%) vs 4,340/38,110 (11.4%); RR 0.94 (95% CI 0.91 to 0.98); P = 0.002; I(2) = 0%; 75,927 participants; 38 trials

    PMID 24414552 · one of two readings recorded this

  • Cancer mortality

    decreases, p = 0.02, n = 44492

    Vitamin D3 statistically significantly decreased cancer mortality (RR 0.88 (95% CI 0.78 to 0.98); P = 0.02; I(2) = 0%; 44,492 participants; 4 trials

    PMID 24414552 · one of two readings recorded this

  • Hypercalcaemia

    increases, p = 0.02, n = 710

    Alfacalcidol and calcitriol increased the risk of hypercalcaemia (RR 3.18 (95% CI 1.17 to 8.68); P = 0.02; I(2) = 17%; 710 participants; 3 trials

    PMID 24414552 · one of two readings recorded this

  • Nephrolithiasis

    increases, p = 0.02, n = 42876

    Vitamin D3 combined with calcium increased the risk of nephrolithiasis (RR 1.17 (95% CI 1.02 to 1.34); P = 0.02; I(2) = 0%; 42,876 participants; 4 trials

    PMID 24414552 · one of two readings recorded this

  • Number needed to treat to prevent one additional death (trial sequential analysis, vitamin D3)

    decreases

    corresponding to 150 people treated over five years to prevent one additional death

    PMID 24414552 · one of two readings recorded this

  • Cardiovascular mortality

    increases

    were 1.35 (95% confidence interval 1.13 to 1.61) for death from cardiovascular disease (6416 events)

    PMID 24690623 · one of two readings recorded this

  • all-cause mortality in randomised trials of vitamin D2 supplementation given alone versus placebo or no treatment (eight trials), random-effects pooled risk ratio

    Not recorded as a finding: the direction is carried only as a signed number

    The corresponding risk ratios according to type of vitamin D supplementation was 0.89 (0.80 to 0.99) for vitamin D3 and 1.04 (0.97 to 1.11) for vitamin D2 (fig 6).

    PMID 24690623 · one of two readings recorded this

  • all-cause mortality, pooled risk ratio, vitamin D2 supplementation alone versus placebo or no treatment (208 to 4500 IU/day, eight trials)

    Not recorded as a finding: the direction is carried only as a signed number

    The corresponding risk ratios according to type of vitamin D supplementation was 0.89 (0.80 to 0.99) for vitamin D3 and 1.04 (0.97 to 1.11) for vitamin D2 (fig 6).

    PMID 24690623 · one of two readings recorded this

  • All cause mortality

    no effect

    a total of 2527 all cause mortality events occurred among participants in the intervention group compared with 2587 events in the control group, with a combined risk ratio of 0.98 (0.94 to 1.02) in all studies

    PMID 24690623 · one of two readings recorded this

  • All cause mortality

    no effect

    The corresponding risk ratios according to type of vitamin D supplementation was 0.89 (0.80 to 0.99) for vitamin D3 and 1.04 (0.97 to 1.11) for vitamin D2 (fig 6)

    PMID 24690623 · one of two readings recorded this

  • All cause mortality

    decreases

    The corresponding risk ratios according to type of vitamin D supplementation was 0.89 (0.80 to 0.99) for vitamin D3 and 1.04 (0.97 to 1.11) for vitamin D2 (fig 6)

    PMID 24690623 · one of two readings recorded this

  • All cause mortality

    increases

    1.35 (1.22 to 1.49) for all cause mortality (48 488 events)

    PMID 24690623 · one of two readings recorded this

  • All cause mortality

    increases

    each 10 ng/mL decline of 25-hydroxyvitamin D concentration was associated with a 16% (95% confidence interval 8% to 23%) increased risk of all cause mortality

    PMID 24690623 · one of two readings recorded this

  • Cancer mortality

    increases

    1.14 (1.01 to 1.29) for death from cancer (5003 events)

    PMID 24690623 · one of two readings recorded this

  • Estimated absolute risk difference for all cause mortality associated with vitamin D deficiency

    were 75.4 events in Europe and 96.6 events in the United States, per 100 000 population, per year

    PMID 24690623 · one of two readings recorded this

  • Other non-vascular, non-cancer mortality

    increases

    1.30 (1.07 to 1.59) for other non-vascular, non-cancer death (1444 events)

    PMID 24690623 · one of two readings recorded this

  • Prevalence of severe deficiency (25(OH)D <10 ng/mL) in general population

    using 25-hydroxyvitamin D concentrations less than 10 ng/mL as the criterion, 4% and 15% of the general population were severely deficient in the Europe and United States, respectively

    PMID 24690623 · one of two readings recorded this

  • Prevalence of vitamin D insufficiency (25(OH)D <30 ng/mL)

    86.4% (78.4% to 95.2%) for Europe

    PMID 24690623 · one of two readings recorded this

  • Prevalence of vitamin D insufficiency (25(OH)D <30 ng/mL)

    the prevalence of vitamin D insufficiency (defined as 25-hydroxyvitamin D concentration <30 ng/mL) was 69.5% (95% confidence interval 62.1% to 77.7%) for the United States

    PMID 24690623 · one of two readings recorded this

  • Proportion of all deaths attributable to vitamin D deficiency

    9.4% of all deaths in Europe and 12.8% of those in the United States could be attributed to vitamin D deficiency

    PMID 24690623 · one of two readings recorded this

  • All-cause mortality

    decreases, p = 0.009

    Vitamin D decreased all-cause mortality (1854/24,846 (7.5%) versus 2007/25,020 (8.0%); RR 0.93 (95% CI 0.88 to 0.98); P = 0.009

    PMID 24953955 · one of two readings recorded this

  • Cancer mortality

    decreases, p = 0.02

    Vitamin D₃ decreased cancer mortality (558/22,286 (2.5%) versus 634/22,206 (2.8%); RR 0.88 (95% CI 0.78 to 0.98); P = 0.02

    PMID 24953955 · one of two readings recorded this

  • cancer occurrence, all-cause mortality, cancer mortality and nephrolithiasis for vitamin D supplementation pooled across vitamin D3 (14 trials), vitamin D2 (1 trial) and calcitriol (3 trials); no vitamin D2-specific estimate in the abstract

    no effect, p = 0.88, n = 50623

    Not recorded as a finding: another reason, stated per paper

    Cancer occurrence was observed in 1927/25,275 (7.6%) recipients of vitamin D versus 1943/25,348 (7.7%) recipients of control interventions (RR 1.00 (95% confidence interval (CI) 0.94 to 1.06); P = 0.88; I² = 0%; 18 trials; 50,623 participants; moderate quality evidence according to the GRADE instrument).

    PMID 24953955 · one of two readings recorded this

  • Cancer occurrence

    no effect, p = 0.88

    Cancer occurrence was observed in 1927/25,275 (7.6%) recipients of vitamin D versus 1943/25,348 (7.7%) recipients of control interventions (RR 1.00 (95% confidence interval (CI) 0.94 to 1.06); P = 0.88

    PMID 24953955 · one of two readings recorded this

  • Cancer occurrence

    no effect, p = 0.88

    Cancer occurrence was observed in 1918/24,908 (7.7%) recipients of vitamin D₃ versus 1933/24,983 (7.7%) in recipients of control interventions (RR 1.00 (95% CI 0.94 to 1.06); P = 0.88

    PMID 24953955 · one of two readings recorded this

  • Nephrolithiasis

    increases, p = 0.02

    Vitamin D₃ combined with calcium increased nephrolithiasis (RR 1.17 (95% CI 1.03 to 1.34); P = 0.02

    PMID 24953955 · one of two readings recorded this

  • HDL cholesterol

    decreases

    In the D2 group there were small, but statistically significant, decreases from baseline relative to placebo in total cholesterol and ApoB (favouring D2), as well as in HDL cholesterol and ApoA1 (favouring placebo; Figure 4A)

    PMID 26700109 · one of two readings recorded this

  • apolipoprotein A1

    decreases

    In the D2 group there were small, but statistically significant, decreases from baseline relative to placebo in total cholesterol and ApoB (favouring D2), as well as in HDL cholesterol and ApoA1 (favouring placebo; Figure 4A)

    PMID 26700109 · one of two readings recorded this

  • 25(OH)D2 change from baseline

    increases

    in the D2 group, the mean 25(OH)D2 concentration increased by 48.7 (19.2) nmol/l, while the 25(OH)D3 concentration decreased by 17.5 (22.1) nmol/l, and total 25(OH)D concentration increased by 31.2 (28.6) nmol/l

    PMID 26700109 · one of two readings recorded this

  • 25(OH)D3 change from baseline

    decreases

    in the D2 group, the mean 25(OH)D2 concentration increased by 48.7 (19.2) nmol/l, while the 25(OH)D3 concentration decreased by 17.5 (22.1) nmol/l, and total 25(OH)D concentration increased by 31.2 (28.6) nmol/l

    PMID 26700109 · one of two readings recorded this

  • 25(OH)D3 change from baseline

    increases

    25(OH)D3 and total 25(OH)D concentrations increased by 38.3 (24.2) nmol/l and 38.1 (23.8) nmol/l, respectively

    PMID 26700109 · one of two readings recorded this

  • anthropometric measures, blood pressure, hsCRP, CVD risk, hepatic markers, fructosamine

    no effect

    Among the secondary outcomes, there were no differences comparing D2 with placebo or D3 with placebo for anthropometric measures, blood pressure, hsCRP, CVD risk, assessed by UKPDS risk engine, hepatic markers, or fructosamine

    PMID 26700109 · one of two readings recorded this

  • apolipoprotein B

    decreases

    In the D2 group there were small, but statistically significant, decreases from baseline relative to placebo in total cholesterol and ApoB (favouring D2), as well as in HDL cholesterol and ApoA1 (favouring placebo; Figure 4A)

    PMID 26700109 · one of two readings recorded this

  • apolipoprotein B

    decreases

    In the D3 group, there was a very small decrease in ApoB concentration between baseline and follow‐up relative to placebo

    PMID 26700109 · one of two readings recorded this

  • fructosamine difference (post hoc)

    no effect

    D3 versus D2: −2.94 (95% CI −8.37, 2.48) µmol/l

    PMID 26700109 · one of two readings recorded this

  • HbA1c change from baseline (mmol/mol)

    no effect, p = 0.13

    the difference comparing D2 with placebo was −0.05% (95% CI −0.11, 0.02) or −0.51 (95% CI −1.16, 0.14) mmol/mol (p = 0.13)

    PMID 26700109 · one of two readings recorded this

  • HbA1c change from baseline (mmol/mol)

    no effect, p = 0.57

    for D3 versus placebo it was 0.02% (95% CI −0.04%, 0.08%) or 0.19 (95% CI −0.46, 0.83) mmol/mol (p = 0.57)

    PMID 26700109 · one of two readings recorded this

  • HbA1c change from baseline (%)

    no effect, p = 0.13

    the difference comparing D2 with placebo was −0.05% (95% CI −0.11, 0.02) or −0.51 (95% CI −1.16, 0.14) mmol/mol (p = 0.13)

    PMID 26700109 · one of two readings recorded this

  • HbA1c change from baseline (%)

    no effect, p = 0.57

    for D3 versus placebo it was 0.02% (95% CI −0.04%, 0.08%) or 0.19 (95% CI −0.46, 0.83) mmol/mol (p = 0.57)

    PMID 26700109 · one of two readings recorded this

  • HbA1c difference (mmol/mol)

    no effect

    there was no evidence of a treatment effect [D3 vs D2: 0.06% (95%CI −0.005, 0.13%) or 0.66 (95% CI −0.05, 1.38) mmol/mol]

    PMID 26700109 · one of two readings recorded this

  • HbA1c difference (%)

    no effect

    there was no evidence of a treatment effect [D3 vs D2: 0.06% (95%CI −0.005, 0.13%) or 0.66 (95% CI −0.05, 1.38) mmol/mol]

    PMID 26700109 · one of two readings recorded this

  • parathyroid hormone, serum

    no effect

    Not recorded as a finding: no_outcome_node: no parathyroid hormone node

    There was an increase in PTH in the D2 group, but the difference between D2 and placebo was not statistically significant.

    PMID 26700109 · one of two readings recorded this

  • parathyroid hormone

    no effect

    There was an increase in PTH in the D2 group, but the difference between D2 and placebo was not statistically significant

    PMID 26700109 · one of two readings recorded this

  • parathyroid hormone

    decreases

    There was a decrease in PTH in the D3 group between baseline and follow‐up that was significantly different from the increase seen in the placebo group

    PMID 26700109 · one of two readings recorded this

  • proportion with 25(OH)D <50 nmol/l at baseline

    The percentages of individuals with a 25(OH)D concentration <50 nmol/l at baseline were 58.8, 50.9 and 50.9% in the placebo, D2 and D3 groups, respectively

    PMID 26700109 · one of two readings recorded this

  • proportion with 25(OH)D <50 nmol/l at baseline

    The percentages of individuals with a 25(OH)D concentration <50 nmol/l at baseline were 58.8, 50.9 and 50.9% in the placebo, D2 and D3 groups, respectively

    PMID 26700109 · one of two readings recorded this

  • proportion with 25(OH)D <50 nmol/l at baseline

    The percentages of individuals with a 25(OH)D concentration <50 nmol/l at baseline were 58.8, 50.9 and 50.9% in the placebo, D2 and D3 groups, respectively

    PMID 26700109 · one of two readings recorded this

  • proportion with 25(OH)D <50 nmol/l at follow-up

    decreases

    at follow‐up these percentages were 47.3, 4.5 and 3.5%

    PMID 26700109 · one of two readings recorded this

  • proportion with 25(OH)D <50 nmol/l at follow-up

    decreases

    at follow‐up these percentages were 47.3, 4.5 and 3.5%

    PMID 26700109 · one of two readings recorded this

  • proportion with 25(OH)D <50 nmol/l at follow-up

    at follow‐up these percentages were 47.3, 4.5 and 3.5%

    PMID 26700109 · one of two readings recorded this

  • pulse wave velocity change from baseline

    decreases

    in both the D2 [mean (s.d.) −0.17 (2.5) m/s] and D3 [mean (s.d.) −0.75 (2.1) m/s] groups

    PMID 26700109 · one of two readings recorded this

  • pulse wave velocity change from baseline

    decreases

    in both the D2 [mean (s.d.) −0.17 (2.5) m/s] and D3 [mean (s.d.) −0.75 (2.1) m/s] groups

    PMID 26700109 · one of two readings recorded this

  • pulse wave velocity, handheld Doppler carotid-femoral, treatment difference versus placebo

    decreases, D2 vs placebo -0.68 m/s (95% CI -1.31, -0.05)

    Not recorded as a finding: endpoint_near_miss: carotid-femoral PWV node specifies applanation tonometry or a validated oscillometric device; the paper used handheld ultrasonic Doppler velocimeters, and the segment is stated so the unspecified-segment node does not fit either

    There was a reduction from baseline in PWV in both the D2 [mean (s.d.) −0.17 (2.5) m/s] and D3 [mean (s.d.) −0.75 (2.1) m/s] groups, relative to placebo [treatment difference D2 vs placebo: −0.68 (95% CI −1.31,−0.05) m/s; D3 vs placebo: −0.73 (95% CI −1.42, −0.03) m/s; Figure 4A, B].

    PMID 26700109 · one of two readings recorded this

  • pulse wave velocity treatment difference vs placebo

    decreases

    treatment difference D2 vs placebo: −0.68 (95% CI −1.31,−0.05) m/s; D3 vs placebo: −0.73 (95% CI −1.42, −0.03) m/s

    PMID 26700109 · one of two readings recorded this

  • pulse wave velocity treatment difference vs placebo

    decreases

    the treatment differences were −0.79 (95% CI −1.43, −0.14) m/s for D2 versus placebo, and −1.01 (95% CI −1.69, −0.34) m/s for D3 versus placebo

    PMID 26700109 · one of two readings recorded this

  • pulse wave velocity treatment difference vs placebo

    decreases

    treatment difference D2 vs placebo: −0.68 (95% CI −1.31,−0.05) m/s; D3 vs placebo: −0.73 (95% CI −1.42, −0.03) m/s

    PMID 26700109 · one of two readings recorded this

  • pulse wave velocity treatment difference vs placebo

    decreases

    the treatment differences were −0.79 (95% CI −1.43, −0.14) m/s for D2 versus placebo, and −1.01 (95% CI −1.69, −0.34) m/s for D3 versus placebo

    PMID 26700109 · one of two readings recorded this

  • serum 25(OH)D2

    increases

    Mean (s.d.) 25(OH)D2 concentrations increased in the D2 group from 5.2 (4.1) nmol/l to 53.9 (18.5) nmol/l

    PMID 26700109 · one of two readings recorded this

  • serum 25(OH)D3

    increases

    mean (s.d.) 25(OH)D3 concentrations increased from 45.8 (22.6) nmol/l to 83.8 (22.7) nmol/l in the D3 group

    PMID 26700109 · one of two readings recorded this

  • total 25(OH)D change from baseline

    increases

    in the D2 group, the mean 25(OH)D2 concentration increased by 48.7 (19.2) nmol/l, while the 25(OH)D3 concentration decreased by 17.5 (22.1) nmol/l, and total 25(OH)D concentration increased by 31.2 (28.6) nmol/l

    PMID 26700109 · one of two readings recorded this

  • total 25(OH)D change from baseline

    increases

    25(OH)D3 and total 25(OH)D concentrations increased by 38.3 (24.2) nmol/l and 38.1 (23.8) nmol/l, respectively

    PMID 26700109 · one of two readings recorded this

  • total cholesterol

    decreases

    In the D2 group there were small, but statistically significant, decreases from baseline relative to placebo in total cholesterol and ApoB (favouring D2), as well as in HDL cholesterol and ApoA1 (favouring placebo; Figure 4A)

    PMID 26700109 · one of two readings recorded this

  • blood pressure between groups

    no effect, p = 0.941

    Of note, there was no significant difference in blood pressure between groups at 12-month follow-up (P = 0.941)

    PMID 26711179 · one of two readings recorded this

  • left atrial volume change

    increases, p = 0.0025

    In the placebo group, left atrial volume significantly increased on follow-up (LA volume increased 6.3 mL, P = 0.0025)

    PMID 26711179 · one of two readings recorded this

  • left atrial volume change

    no effect, p = 0.29

    Compared with placebo group, the treatment group with ergocalciferol had attenuated increases in left atrial volume (LA volume increased 2.6 mL, P = 0.29)

    PMID 26711179 · one of two readings recorded this

  • left atrial volume, echocardiography biplane Simpson's method, change over 12 months

    decreases

    Not recorded as a finding: no_outcome_node: no left atrial volume node; the listed LVEF and E/e' nodes are different measures

    Compared with placebo group, the treatment group with ergocalciferol had attenuated increases in left atrial volume (LA volume increased 2.6 mL, P = 0.29).

    PMID 26711179 · one of two readings recorded this

  • left ventricular ejection fraction and wall thickness

    no effect

    Left ventricular ejection fraction and wall thickness did not change significantly in either group, as well as parameters evaluating diastolic function (IVRT, DT, septal E′, lateral E′)

    PMID 26711179 · one of two readings recorded this

  • serum 25(OH)D at 12 months

    increases, p = 0.001

    At 12 months, the mean serum 25(OH) vit D level had increased to 50.5 ± 24.1 ng/mL in the treatment group and to 20.18 ± 9.6 ng/mL in the placebo group (between groups P < 0.001)

    PMID 26711179 · one of two readings recorded this

  • serum 25(OH)D at 12 months

    increases

    At 12 months, the mean serum 25(OH) vit D level had increased to 50.5 ± 24.1 ng/mL in the treatment group and to 20.18 ± 9.6 ng/mL in the placebo group (between groups P < 0.001)

    PMID 26711179 · one of two readings recorded this

  • baseline free 25D

    no effect, p = 0.8

    Baseline total (22.2 ± 3.3 vs 23.3 ± 7.2 ng/mL; P = .5) and free (5.4 ± 0.8 vs 5.3 ± 1.7 pg/mL; P = .8) 25D levels were similar between D2 and D3 groups

    PMID 27192696 · one of two readings recorded this

  • baseline total 25D

    no effect, p = 0.5

    Baseline total (22.2 ± 3.3 vs 23.3 ± 7.2 ng/mL; P = .5) and free (5.4 ± 0.8 vs 5.3 ± 1.7 pg/mL; P = .8) 25D levels were similar between D2 and D3 groups

    PMID 27192696 · one of two readings recorded this

  • increase in free 25D

    increases, p = 0.02

    and free (+3.6 vs +6.2 pg/mL; P = .02) 25D levels were greater with D3 vs D2

    PMID 27192696 · one of two readings recorded this

  • increase in total 25D

    increases, p = 0.001

    Increases in total (+27.6 vs +12.2 ng/mL; P = .001)

    PMID 27192696 · one of two readings recorded this

  • percentage change in iPTH association with change in free 25D

    unclear

    Percentage change in iPTH was significantly associated with change in free (but not total) 25D, without and with adjustment for supplementation regimen, change in 1,25-dihydroxyvitamin D, and change in calcium

    PMID 27192696 · one of two readings recorded this

  • serum total 25(OH)D and directly measured free 25(OH)D, change from baseline to 10 weeks, vitamin D2 versus vitamin D3 at 50,000 IU twice weekly for 5 weeks

    decreases

    Not recorded as a finding: the comparison was against another active treatment

    D3 increased total and free 25D levels to a greater extent than D2.

    PMID 27192696 · one of two readings recorded this

  • 25(OH)D AUC140 (adjusted for sex, BMI, baseline 25(OH)D)

    increases, p = 0.001

    AUC from day 0 to 140 (AUC140) of 25(OH)D was 40% (D3 daily) to 55% (D3 2-weekly) higher with active-treatment than placebo (p < 0.001)

    PMID 28231782 · one of two readings recorded this

  • 25(OH)D AUC140 (adjusted for sex, BMI, baseline 25(OH)D)

    increases, p = 0.001

    AUC from day 0 to 140 (AUC140) of 25(OH)D was 40% (D3 daily) to 55% (D3 2-weekly) higher with active-treatment than placebo (p < 0.001)

    PMID 28231782 · one of two readings recorded this

  • 25(OH)D2 AUC140

    increases, p = 0.001

    25(OH)D2 AUC140 was higher in daily than 2-weekly (17%, p = 0.006) and 4-weekly (20%, p = 0.001) D2-treated groups

    PMID 28231782 · one of two readings recorded this

  • 25(OH)D2 AUC140

    increases, p = 0.006

    25(OH)D2 AUC140 was higher in daily than 2-weekly (17%, p = 0.006) and 4-weekly (20%, p = 0.001) D2-treated groups

    PMID 28231782 · one of two readings recorded this

  • 25(OH)D3 AUC140

    decreases, p = 0.008

    25(OH)D3 AUC140 was lower in daily than 2-weekly (11%, p = 0.002) and 4-weekly D3-treated groups (10%, p = 0.008)

    PMID 28231782 · one of two readings recorded this

  • 25(OH)D3 AUC140

    decreases, p = 0.002

    25(OH)D3 AUC140 was lower in daily than 2-weekly (11%, p = 0.002) and 4-weekly D3-treated groups (10%, p = 0.008)

    PMID 28231782 · one of two readings recorded this

  • 25(OH)D3 level decrease in D2-treated groups

    decreases

    In D2-treated groups, there was 16.4 nmol/L decrease in 25(OH)D3 level that correlated (p < 0.001) with 25(OH)D2 level increase (r = 0.48) and baseline 25(OH)D level (r = 0.58)

    PMID 28231782 · one of two readings recorded this

  • area under the curve of serum 25(OH)D (25(OH)D2 + 25(OH)D3) from day 0 to day 140, by high performance liquid chromatography; active-treatment arms pooled D2 and D3 against placebo

    increases, AUC140 40% (D3 daily) to 55% (D3 2-weekly) higher with active treatment than placebo

    Not recorded as a finding: this platform holds no node for the endpoint

    AUC from day 0 to 140 (AUC140) of 25(OH)D was 40% (D3 daily) to 55% (D3 2-weekly) higher with active-treatment than placebo (p < 0.001).

    PMID 28231782 · one of two readings recorded this

  • baseline 25(OH)D as predictor of response to D2 and D3

    unclear, p = 0.001

    Baseline 25(OH)D level predicted response to D2 and D3 (p < 0.001)

    PMID 28231782 · one of two readings recorded this

  • correlation of 25(OH)D3 decrease with 25(OH)D2 increase

    unclear, p = 0.001

    In D2-treated groups, there was 16.4 nmol/L decrease in 25(OH)D3 level that correlated (p < 0.001) with 25(OH)D2 level increase (r = 0.48) and baseline 25(OH)D level (r = 0.58)

    PMID 28231782 · one of two readings recorded this

  • correlation of 25(OH)D3 decrease with baseline 25(OH)D

    unclear, p = 0.001

    In D2-treated groups, there was 16.4 nmol/L decrease in 25(OH)D3 level that correlated (p < 0.001) with 25(OH)D2 level increase (r = 0.48) and baseline 25(OH)D level (r = 0.58)

    PMID 28231782 · one of two readings recorded this

  • incremental AUC7 of D3 and 25(OH)D3 in D3-treated groups versus D2 and 25(OH)D2 in D2-treated groups

    modulates

    Incremental AUC from day 0 to 7 (AUC7) of D3 and 25(OH)D3 in D3-treated groups were 118-243% higher and 31-39% lower, respectively

    PMID 28231782 · one of two readings recorded this

  • incremental AUC7 response by sex

    increases

    Incremental AUC7 of D3 and 25(OH)D3 in D3-treated groups and D2 and 25(OH)D2 in D2-treated groups were higher in females than males (55, 13, 64, and 28%, respectively)

    PMID 28231782 · one of two readings recorded this

  • serum 25(OH)D change from baseline

    increases

    Baseline 25(OH)D level was 39.8(11.9) and increased by 3.3(11.6) and 28.6(16.3) nmol/L, in the placebo and active-treatment groups, respectively

    PMID 28231782 · one of two readings recorded this

  • serum 25(OH)D change from baseline

    no effect

    Baseline 25(OH)D level was 39.8(11.9) and increased by 3.3(11.6) and 28.6(16.3) nmol/L, in the placebo and active-treatment groups, respectively

    PMID 28231782 · one of two readings recorded this

  • 25OH-D3 dose giving serum vitamin D status similar to 10 µg vitD3

    modulates

    Based on the assumption that 1 µg vitD3/day will show an increase in vitamin D status of 1.96 nmol/L, the results showed that 23 µg vitD2 and 6.8 µg 25OH-D3 was similar to 10 µg vitD3

    PMID 29295513 · one of two readings recorded this

  • increase in vitamin D status per 1 µg vitD3/day (assumed)

    increases

    Based on the assumption that 1 µg vitD3/day will show an increase in vitamin D status of 1.96 nmol/L, the results showed that 23 µg vitD2 and 6.8 µg 25OH-D3 was similar to 10 µg vitD3

    PMID 29295513 · one of two readings recorded this

  • serum 25-hydroxyvitamin D (vitamin D status) by LC-MS/MS after 6 weeks each of 10 ug/day vitamin D3, 25OH-D3 and vitamin D2 in a crossover

    Not recorded as a finding: the comparison was against another active treatment

    The hypothesis that the three sources of vitamin D affect vitamin D status equally was rejected.

    PMID 29295513 · one of two readings recorded this

  • vitD2 dose giving serum vitamin D status similar to 10 µg vitD3

    modulates

    Based on the assumption that 1 µg vitD3/day will show an increase in vitamin D status of 1.96 nmol/L, the results showed that 23 µg vitD2 and 6.8 µg 25OH-D3 was similar to 10 µg vitD3

    PMID 29295513 · one of two readings recorded this

  • Annualised relapse rate

    no effect, n = 417

    Vitamin D₃ had no effect on the annualised relapse rate at 52 weeks' follow-up (rate difference -0.05, 95% CI -0.17 to 0.07; I² = 38%; five trials; 417 participants

    PMID 30246874 · one of two readings recorded this

  • Expanded Disability Status Scale

    no effect, n = 221

    on the Expanded Disability Status Scale at 52 weeks' follow-up (MD -0.25, 95% CI -0.61 to 0.10; I² = 35%; five trials; 221 participants

    PMID 30246874 · one of two readings recorded this

  • Fatigue

    no effect, n = 71

    The other study (71 participants) found no effect on fatigue at 96 weeks' follow-up

    PMID 30246874 · one of two readings recorded this

  • Fatigue

    decreases, n = 158

    One study (158 participants) reported that vitamin D₃ reduced fatigue compared with placebo at 26 weeks' follow-up

    PMID 30246874 · one of two readings recorded this

  • Minor adverse effects

    no effect, n = 701

    or minor adverse effects within a range of 26 to 96 weeks' follow-up (RD 0.02, 95% CI -0.02 to 0.06; I² = 20%; eight trials; 701 participants

    PMID 30246874 · one of two readings recorded this

  • MRI gadolinium-enhancing T1 lesions

    no effect, n = 256

    on MRI gadolinium-enhancing T1 lesions at 52 weeks' follow-up (MD 0.02, 95% CI -0.45 to 0.48; I² = 12%; two trials; 256 participants

    PMID 30246874 · one of two readings recorded this

  • Serious adverse effects

    no effect, n = 621

    Vitamin D₃ did not increase the risk of serious adverse effects within a range of 26 to 52 weeks' follow-up (RD 0.01, 95% CI -0.03 to 0.04; I² = 35%; eight trials; 621 participants

    PMID 30246874 · one of two readings recorded this

  • lumbar spine BMD at week 24, between groups

    increases, p = 0.042, n = 18

    At week 24, the mean (SD) lumbar spine BMD was significantly greater in the study group than in the control group (p = 0.042)

    PMID 31906840 · one of two readings recorded this

  • lumbar spine BMD

    decreases, p = 0.006, n = 9

    from 0.90 (0.09) g/cm3 to 0.86 (0.08) g/cm2 in the control group (p = 0.006)

    PMID 31906840 · one of two readings recorded this

  • lumbar spine BMD

    decreases, p = 0.004, n = 9

    from 1.00 (0.13) g/cm2 to 0.97 (0.13) g/cm2 (p = 0.004) in the study group

    PMID 31906840 · one of two readings recorded this

  • percentage change in total hip, lumbar spine and femoral neck BMD

    no effect, n = 18

    there were no significant differences in the percentage change of total hip, lumbar spine, and femoral neck BMD between both groups

    PMID 31906840 · one of two readings recorded this

  • percentage change in total hip, lumbar spine and femoral neck bone mineral density at week 24 versus baseline

    no effect

    Not recorded as a finding: the intervention held more than the compound

    However, there were no significant differences in the percentage change of total hip, lumbar spine, and femoral neck BMD between both groups.

    PMID 31906840 · one of two readings recorded this

  • percentage change in total hip, lumbar spine and femoral neck bone mineral density at week 24

    no effect

    Not recorded as a finding: the intervention held more than the compound

    However, there were no significant differences in the percentage change of total hip, lumbar spine, and femoral neck BMD between both groups.

    PMID 31906840 · one of two readings recorded this

  • total hip BMD

    decreases, p = 0.004, n = 9

    from 0.87 (0.11) g/cm2 to 0.84 (0.11) g/cm2 in the control group (p = 0.004)

    PMID 31906840 · one of two readings recorded this

  • total hip BMD

    decreases, p = 0.006, n = 9

    from 0.96 (0.14) g/cm2 to 0.93 (0.13) g/cm2 in the study group (p = 0.006)

    PMID 31906840 · one of two readings recorded this

  • serum 25(OH)D2, 25(OH)D3 and 25(OH)D total over 12 weeks, liquid chromatography mass spectrometry; mushroom-derived vitamin D2 versus vitamin D3 versus placebo

    +14% in 25(OH)DTOTAL with D2 by week 12

    Not recorded as a finding: a direction is stated and the estimate does not support it

    A net + 14% increase in 25(OH)DTOTAL was established with D2 supplementation by week 12 (p > 0.05), which was not statistically different to D3.

    PMID 33176826 · one of two readings recorded this

  • serum 25(OH)D2

    increases, p = 0.0001

    D2 supplementation increased 25(OH)D2 by + 347% (7.0 ± 1.1 nmol·L- 1 to 31.4 ± 2.1 nmol·L- 1, p < 0.0001)

    PMID 33176826 · one of two readings recorded this

  • serum 25(OH)D3

    decreases, p = 0.001

    resulted in a - 42% reduction in 25(OH)D3 by week 6 (p = 0.001)

    PMID 33176826 · one of two readings recorded this

  • serum 25(OH)D3

    increases, p = 0.0001

    an expected rise in 25(OH)D3 concentrations from 38.8 ± 5.2 nmol·L- 1 to 82.0 ± 7.9 nmol·L- 1 (p < 0.0001)

    PMID 33176826 · one of two readings recorded this

  • serum 25(OH)DTOTAL

    no effect, p = 0.05

    A net + 14% increase in 25(OH)DTOTAL was established with D2 supplementation by week 12 (p > 0.05)

    PMID 33176826 · one of two readings recorded this

  • serum 25(OH)DTOTAL

    decreases, p = 0.046

    Vitamin D status was maintained with PL, following an initial - 15% reduction by week 6 (p ≤ 0.046 compared to both supplement groups)

    PMID 33176826 · one of two readings recorded this

  • serum 25(OH)DTOTAL

    increases, p = 0.0001

    Vitamin D status (25(OH)DTOTAL) was significantly increased with vitamin D3 supplementation from 46.1 ± 5.3 nmol·L- 1 to 88.0 ± 8.6 nmol·L- 1 (p < 0.0001)

    PMID 33176826 · one of two readings recorded this

  • serum total 25(OH)D (25(OH)D2 plus 25(OH)D3) by liquid chromatography mass spectrometry, baseline to week 12, mushroom-derived vitamin D2 versus vitamin D3 versus placebo

    increases, +14% in 25(OH)D total with D2 by week 12

    Not recorded as a finding: the result compares a group with itself, not with a control

    A net + 14% increase in 25(OH)DTOTAL was established with D2 supplementation by week 12 (p > 0.05), which was not statistically different to D3.

    PMID 33176826 · one of two readings recorded this

  • cognitive function and mood measures

    no effect, n = 436

    There were no significant effects of treatment on any of the measures of cognitive function or mood

    PMID 33339304 · one of two readings recorded this

  • cognitive performance and mood measures over 24 weeks, with serum 25-OH-D, 25-OH-D2 and 25-OH-D3 as co-primary endpoints; arms were vitamin D3, vitamin D2-enhanced mushroom matrix, standard mushroom and placebo

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    There were no significant effects of treatment on any of the measures of cognitive function or mood.

    PMID 33339304 · one of two readings recorded this

  • serum total 25-OH-D and 25-OH-D3

    decreases, p = 0.05

    Levels of total 25-OH-D and 25-OH-D3 were maintained in the D3 arm but decreased significantly (p < 0.05) in the remaining arms (D2M, SM and PL)

    PMID 33339304 · one of two readings recorded this

  • serum total 25-OH-D and 25-OH-D3

    no effect

    Levels of total 25-OH-D and 25-OH-D3 were maintained in the D3 arm but decreased significantly (p < 0.05) in the remaining arms (D2M, SM and PL)

    PMID 33339304 · one of two readings recorded this

  • ambulatory status: independent without gait aid

    no effect, p = 0.514, n = 119

    - Independent without gait aid | 28 (45.9) | 21 (36.2) | 0.514

    PMID 33478397 · one of two readings recorded this

  • ambulatory status: pick up walker

    no effect, n = 119

    - Pick up walker | 20 (32.8) | 22 (37.9)

    PMID 33478397 · one of two readings recorded this

  • ambulatory status: single cane

    no effect, n = 119

    - Single cane | 5 (8.2) | 5 (8.6)

    PMID 33478397 · one of two readings recorded this

  • ambulatory status: tripod cane

    no effect, n = 119

    - Tripod cane | 0 (0.0) | 2 (3.4)

    PMID 33478397 · one of two readings recorded this

  • ambulatory status: wheel chair

    no effect, n = 119

    - Wheel chair | 2 (3.3) | 4 (6.9)

    PMID 33478397 · one of two readings recorded this

  • Barthel Index and EQ-VAS, difference between groups

    no effect, n = 119

    However, there was no significant difference when comparing between the 2 groups

    PMID 33478397 · one of two readings recorded this

  • corrected serum calcium, baseline to 12 weeks

    increases, p = 0.001

    8.8 ± 0.4 mg/dL to 9.3 ± 0.5 mg/dL in the low-dose group, p < 0.001

    PMID 33478397 · one of two readings recorded this

  • corrected serum calcium, baseline to 12 weeks

    increases, p = 0.001

    8.8 ± 0.6 mg/dL to 9.2 ± 0.6 mg/dL in the high-dose group, p < 0.001

    PMID 33478397 · one of two readings recorded this

  • functional status: bed bound

    no effect, p = 0.374, n = 119

    - Bed bound | 6 (9.8) | 4 (6.9) | 0.374

    PMID 33478397 · one of two readings recorded this

  • functional status: indoor

    no effect, n = 119

    - Indoor | 14 (23.0) | 19 (32.8)

    PMID 33478397 · one of two readings recorded this

  • functional status: outdoor

    no effect, n = 119

    - Outdoor | 41 (67.2) | 35 (60.3)

    PMID 33478397 · one of two readings recorded this

  • post-treatment serum 25(OH)D, between-group difference

    increases, p = 0.001, n = 119

    There was a significant difference in the post-treatment level of serum 25(OH)D between the 2 groups (p < 0.001)

    PMID 33478397 · one of two readings recorded this

  • proportion achieving optimal serum 25(OH)D level

    increases, p = 0.001, n = 119

    The number of patients who achieved optimal serum 25(OH)D level was greater in the high-dose group significantly (82.8 and 52.5% for the high- and low-dose groups, respectively; p < 0.001)

    PMID 33478397 · one of two readings recorded this

  • serum 25(OH)D at 12 weeks

    increases, n = 119

    the mean serum 25(OH)D levels significantly increased to 31.4 ± 8.8 and 40.5 ± 12.5 ng/mL in the low- and high-dose groups, respectively

    PMID 33478397 · one of two readings recorded this

  • serum 25(OH)D at baseline

    no effect, p = 0.249

    Baseline mean serum 25(OH)D levels in the low- and high-dose groups were 20.2 ± 8.2 ng/mL and 18.1 ± 11.1 ng/mL, respectively (p = 0.249)

    PMID 33478397 · one of two readings recorded this

  • serum 25(OH)D concentration at 12 weeks, electrochemiluminescence binding assay on a cobas 8000 analyzer; proportion reaching serum 25(OH)D above 30 ng/mL

    31.4 vs 40.5 ng/mL in the low- and high-dose groups

    Not recorded as a finding: the comparison was against another active treatment

    At the completion of the study, the mean serum 25(OH)D levels significantly increased to 31.4 ± 8.8 and 40.5 ± 12.5 ng/mL in the low- and high-dose groups, respectively.

    PMID 33478397 · one of two readings recorded this

  • serum PTH at 12 weeks

    no effect

    51.8 ± 36.0 pg/mL in the low-dose group, and 56.6 ± 55.5 pg/mL in the high-dose group

    PMID 33478397 · one of two readings recorded this

  • serum PTH at baseline

    The baseline mean serum PTH levels were 41.3 ± 18.4 pg/mL and 50.8 ± 25.3 pg/mL in the low- and high-dose groups, respectively

    PMID 33478397 · one of two readings recorded this

  • change in serum total 25(OH)D, 25(OH)D2 and 25(OH)D3 (nmol/L) and serum PTH, ergocalciferol versus cholecalciferol in apparently healthy adults, 22 studies pooled

    cholecalciferol minus ergocalciferol total 25(OH)D MD 15.69 nmol/L (95% CI 9.46 to 21.93)

    Not recorded as a finding: the comparison was against another active treatment

    On pooling results of the included studies, we found that cholecalciferol intervention elevated total 25(OH)D levels to a greater extent (p < 0.05) as compared to ergocalciferol (mean difference (MD): 15.69 nmol/L, 95% CI: 9.46 to 21.93).

    PMID 34684328 · one of two readings recorded this

  • Serum 25(OH)D2

    decreases

    Ergocalciferol intervention resulted in significantly higher 25(OH)D2 (MD: −27.5 nmol/L (95% CI: −34.24 to −20.76)

    PMID 34684328 · one of two readings recorded this

  • Serum 25(OH)D3

    increases, p = 0.05

    cholecalciferol intervention elevated 25(OH)D3 to a significantly greater extent (MD: 40.85 nmol/L, 95% CI: 31.52 to 50.17, p < 0.05 nmol/L)

    PMID 34684328 · one of two readings recorded this

  • Serum parathyroid hormone (PTH)

    decreases, p = 0.005

    Meta-analysis suggested higher efficacy of cholecalciferol in reducing PTH levels than ergocalciferol (MD: −0.56 pmol/L; 95% CI: −0.93 to −0.18, p = 0.005)

    PMID 34684328 · one of two readings recorded this

  • Serum parathyroid hormone (PTH)

    decreases, p = 0.04

    Subgroup analysis in seven studies with daily intervention reduced heterogeneity (I2 = 0), as well as the magnitude of effect (MD = −0.15 pmol/L, 95% CI: −0.01 to −0.3, p = 0.04)

    PMID 34684328 · one of two readings recorded this

  • serum total 25(OH)D, 25(OH)D2, 25(OH)D3 and serum PTH, ergocalciferol (vitamin D2) versus cholecalciferol, mean difference

    decreases, cholecalciferol raised total 25(OH)D more than ergocalciferol, MD 15.69 nmol/L (95% CI 9.46 to 21.93)

    Not recorded as a finding: the comparison was against another active treatment

    On pooling results of the included studies, we found that cholecalciferol intervention elevated total 25(OH)D levels to a greater extent (p < 0.05) as compared to ergocalciferol (mean difference (MD): 15.69 nmol/L, 95% CI: 9.46 to 21.93).

    PMID 34684328 · one of two readings recorded this

  • Serum total 25(OH)D

    increases, p = 0.05, n = 1277

    cholecalciferol intervention elevated total 25(OH)D levels to a greater extent (p < 0.05) as compared to ergocalciferol (mean difference (MD): 15.69 nmol/L, 95% CI: 9.46 to 21.93)

    PMID 34684328 · one of two readings recorded this

  • Serum total 25(OH)D

    increases

    reduced heterogeneity (I2 = 67%) as well as the effect size (MD: 9.62 nmol/L, 95% CI: 5.82 to 13.43)

    PMID 34684328 · one of two readings recorded this

  • Serum total 25(OH)D

    increases

    when compared to the studies which provided a single bolus dose (MD: 25.06 nmol/L, 95% CI: 3.92 to 46.19)

    PMID 34684328 · one of two readings recorded this

  • arterial stiffness by pulse wave velocity (mixed a-PWv, cf-PWv, ba-PWv and other types pooled), network meta-analysis; the only vitamin D2 contrast stated is against vitamin D3

    vitamin D3 versus vitamin D2 ES -0.25 (95% CI -0.48, -0.02)

    Not recorded as a finding: the comparison was against another active treatment

    In addition, oral vitamin D3 supplementation proved to be a better supplement for decreasing arterial stiffness than vitamin D2 supplementation (ES: −0.25; 95% CI: −0.48, −0.02; −36.0% m/s).

    PMID 35267985 · one of two readings recorded this

  • Arterial stiffness (pulse wave velocity)

    decreases

    for interventions >12 weeks (ES: −0.15; 95% CI: −0.30, −0.00; −60.0% m/s; and ES: −0.25; 95% CI: −0.48, −0.02, −52.0% m/s, respectively)

    PMID 35267985 · one of two readings recorded this

  • Arterial stiffness (pulse wave velocity)

    decreases

    oral vitamin D3 supplementation proved to be a better supplement for decreasing arterial stiffness than vitamin D2 supplementation (ES: −0.25; 95% CI: −0.48, −0.02; −36.0% m/s)

    PMID 35267985 · one of two readings recorded this

  • Arterial stiffness (pulse wave velocity)

    decreases

    central PWv showed significant results in oral supplementation with vitamin D3, compared with oral supplementation with vitamin D2 (ES: −0.25; 95% CI: −0.48, −0.02; −36.0% m/s)

    PMID 35267985 · one of two readings recorded this

  • Arterial stiffness (pulse wave velocity)

    decreases

    for interventions >12 weeks (ES: −0.15; 95% CI: −0.30, −0.00; −60.0% m/s; and ES: −0.25; 95% CI: −0.48, −0.02, −52.0% m/s, respectively)

    PMID 35267985 · one of two readings recorded this

  • Arterial stiffness (pulse wave velocity)

    decreases

    oral supplementation with vitamin D3 was effective in reducing arterial stiffness, compared with oral supplementation with vitamin D2 in adults <65 years (ES: −0.30; 95% CI: −0.57, −0.03; −58.0% m/s)

    PMID 35267985 · one of two readings recorded this

  • Arterial stiffness PWv % change

    no effect

    Dreyer et al., 2014 | United Kingdom | IG: 20 (39.1) CG: 18 (26.3) | IG: 45.8 ± 10.0 CG: 48.8 ± 12.2 | CKD | Ergocalciferol (vit. D2) | 50,000 IU (weekly for one month) + 50,000 IU (monthly) | 16 | a-PWv | Vicorder | IG: 8.5 ± 1.1 CG: 8.5 ± 1.5 | IG: −1.2% CG: 0.0%

    PMID 35267985 · one of two readings recorded this

  • Arterial stiffness PWv % change

    unclear

    Kovesdy et al., 2012 | United States | IG1: 40 (0.0) IG2: 40 (2.0) | IG1: 67.6 ± 9.3 IG2: 69.3 ± 10.6 | CKD | IG1: Ergocalciferol (vit. D2) IG2: Cholecalciferol (vit. D3) | IG1: 50,000 IU (single dose) IG2: 1 or 2 µg (daily) | 16 | a-PWv | Sphygmocor | IG1: 12.8 ± 3.5 IG2: 13.5 ± 3.9 | IG1: 1.6% IG2: −1.5%

    PMID 35267985 · one of two readings recorded this

  • Arterial stiffness PWv % change

    unclear

    Forouhi et al., 2016 | United Kingdom | IG1: 112 (43.8) IG2: 114 (43.0) CG: 114 (42.1) | IG1: 53.5 ± 8.7 IG2: 52.5 ± 8.2 CG: 52.4 ± 8.5 | Pre-DM2 | IG1: Ergocalciferol (vit. D2) IG2: Cholecalciferol (vit. D3) | IG1: 3300 IU (daily) IG2: 3300 IU (daily) | 16 | cf-PWv | Doppler MDII | IG1: 7.3 ± 2.7 IG2: 7.9 ± 2.0 CG: 7.4 ± 2.0 | IG1: −2.3% IG2: −9.5% CG: 4.9%

    PMID 35267985 · one of two readings recorded this

  • Probability of being the best intervention for arterial stiffness

    decreases

    Oral supplementation with vitamin B9 was more likely to be the best (31.0%)

    PMID 35267985 · one of two readings recorded this

  • SUCRA value for arterial stiffness reduction

    decreases

    oral supplementation with vitamin D3 showed a higher SUCRA value (78.0%)

    PMID 35267985 · one of two readings recorded this

  • differentially expressed genes in blood transcriptome, overlap between vitamin D2 and D3

    modulates

    most changes were specific to either one vitamin or the other

    PMID 35281034 · one of two readings recorded this

  • direction of gene expression change after vitamin D3

    decreases

    following vitamin D3 supplementation, the majority of changes in gene expression reflected a down-regulation in the activity of genes

    PMID 35281034 · one of two readings recorded this

  • ethnic differences in transcriptome response

    unclear

    The data also pointed to the possibility of ethnic differences in the responses

    PMID 35281034 · one of two readings recorded this

  • type I and type II interferon-associated gene expression

    increases

    gene expression associated with type I and type II interferon activity, critical to the innate response to bacterial and viral infections, differed following supplementation with either vitamin D2 or vitamin D3, with only vitamin D3 having a stimulatory effect

    PMID 35281034 · one of two readings recorded this

  • Breast milk 25OHD concentration, supplemented vs not supplemented mothers

    no effect

    a significant increase was found in breast milk of mothers receiving vitamin D supplementation in vitamin D3 (MD: 28 IU/L, 95% CI: 6, 50), and ARA (MD: 53, 95% CI: 28, 77), but not vitamin D (MD: 4, 95% CI: -1, 9) or 25OHD (MD: 9, 95% CI: -14, 32)

    PMID 37264448 · one of two readings recorded this

  • Breast milk calcium concentration, calcium supplementation vs control

    no effect

    no significant differences were found between groups of calcium supplementation (mean difference (MD): 4.8 mg/L, 95% CI: -4.4, 14.1)

    PMID 37264448 · one of two readings recorded this

  • Breast milk calcium concentration

    decreases, p = 0.008

    women with conditions 203 mg/L, 95% CI: 171, 234, healthy women 257 mg/L, 95% CI: 232, 281, p = 0.008

    PMID 37264448 · one of two readings recorded this

  • Breast milk total antirachitic activity (ARA), supplemented vs not supplemented mothers

    increases

    a significant increase was found in breast milk of mothers receiving vitamin D supplementation in vitamin D3 (MD: 28 IU/L, 95% CI: 6, 50), and ARA (MD: 53, 95% CI: 28, 77), but not vitamin D (MD: 4, 95% CI: -1, 9) or 25OHD (MD: 9, 95% CI: -14, 32)

    PMID 37264448 · one of two readings recorded this

  • Breast milk total ARA by season

    modulates

    total ARA summer: 117 IU/L, 95% CI: 108, 126, fall: 63 IU/L, 95% CI: 52, 73, winter: 66 IU/L, 95% CI: 45, 87, spring: 58 IU/L, 95% CI: 50, 66

    PMID 37264448 · one of two readings recorded this

  • Breast milk total ARA by vitamin D supplementation status

    increases

    total ARA: 91 IU/L, 95% CI: 73, 109 vs. 48 IU/L, 95% CI: 34, 63

    PMID 37264448 · one of two readings recorded this

  • Breast milk vitamin D concentration, supplemented vs not supplemented mothers

    no effect

    a significant increase was found in breast milk of mothers receiving vitamin D supplementation in vitamin D3 (MD: 28 IU/L, 95% CI: 6, 50), and ARA (MD: 53, 95% CI: 28, 77), but not vitamin D (MD: 4, 95% CI: -1, 9) or 25OHD (MD: 9, 95% CI: -14, 32)

    PMID 37264448 · one of two readings recorded this

  • Breast milk vitamin D3 concentration, supplemented vs not supplemented mothers

    increases

    a significant increase was found in breast milk of mothers receiving vitamin D supplementation in vitamin D3 (MD: 28 IU/L, 95% CI: 6, 50), and ARA (MD: 53, 95% CI: 28, 77), but not vitamin D (MD: 4, 95% CI: -1, 9) or 25OHD (MD: 9, 95% CI: -14, 32)

    PMID 37264448 · one of two readings recorded this

  • Breast milk zinc concentration, zinc supplementation vs control

    no effect

    no significant differences were found between levels of zinc supplementation (MD: 0.11, 95% CI: -0.18, 0.40)

    PMID 37264448 · one of two readings recorded this

  • hemoglobin

    no effect

    No significant changes in hemoglobin were observed

    PMID 37375660 · one of two readings recorded this

  • age at baseline

    The mean age was 28.7 ± 10.7 mo

    PMID 37375660 · one of two readings recorded this

  • baseline dietary vitamin D intake

    At baseline, the mean VD intake was 99.7 ± 183.7 IU/day

    PMID 37375660 · one of two readings recorded this

  • correlation between iPTH and 25(OH)D

    decreases, p = 0.05

    The correlation between iPTH and 25-OH-D was between −0.16 and −0.15 at baseline and after three months (p < 0.05)

    PMID 37375660 · one of two readings recorded this

  • prevalence of vitamin D deficiency

    decreases

    The prevalence of VD deficiency decreased in all three VD-supplemented groups, with the largest effect observed in the 1000 IU D3 group

    PMID 37375660 · one of two readings recorded this

  • serum 25(OH)D change over three months

    increases

    There was a significant and positive change in serum 25-OH-D concentrations over three months of the trial among children in each of the three VD groups but not in the MM non-VD group

    PMID 37375660 · one of two readings recorded this

  • serum 25(OH)D concentration, chemiluminescent microparticle assay (CMIA, Architect analyzer), change over three months

    increases

    Not recorded as a finding: the result compares a group with itself, not with a control

    There was a significant and positive change in serum 25-OH-D concentrations over three months of the trial among children in each of the three VD groups but not in the MM non-VD group (Table 2).

    PMID 37375660 · one of two readings recorded this

  • serum 25(OH)D, other pairwise comparisons, largest change in 1000 IU D3 group

    increases

    with the largest change in the 1000 IU D3 group, followed by the 800 IU D2 group

    PMID 37375660 · one of two readings recorded this

  • serum 25(OH)D, pairwise comparison of 400 IU D2 versus 800 IU D2

    no effect

    For 25-OH-D, no difference was observed between the 400 IU D2 and the 800 IU D2 groups

    PMID 37375660 · one of two readings recorded this

  • serum iPTH

    decreases

    A statistically-significant decrease was observed in iPTH concentrations for the three VD-supplemented groups but not in the MM non-VD group

    PMID 37375660 · one of two readings recorded this

  • supplement compliance rate

    On average, the compliance rate was 75.8% ± 15.1% considering the total days of supplement consumption

    PMID 37375660 · one of two readings recorded this

  • change in serum total 25(OH)D, 25(OH)D2 and 25(OH)D3 concentration, vitamin D2 versus vitamin D3 daily or weekly dosing; LC-MS/MS WMD and other methods pooled as SMD

    decreases, SMD -0.76 (95% CI -1.01, -0.50), smaller change in total 25(OH)D with vitamin D2 than vitamin D3

    Not recorded as a finding: the comparison was against another active treatment

    As shown in Figure 2, the SMD of the meta-analysis was −0.76 (95% CI: −1.01, −0.50; I 2 = 72%; P < 0.00001) indicating a smaller change in total 25(OH)D in the vitamin D2 group compared with the vitamin D3 group.

    PMID 37865222 · one of two readings recorded this

  • change in serum total 25(OH)D (and 25(OH)D2, 25(OH)D3), vitamin D2 versus vitamin D3, SMD or WMD by LC-MS/MS

    decreases, SMD -0.76 (95% CI -1.01, -0.50; I2 = 72%), smaller rise in total 25(OH)D with D2 than D3

    Not recorded as a finding: the comparison was against another active treatment

    As shown in Figure 2, the SMD of the meta-analysis was −0.76 (95% CI: −1.01, −0.50; I 2 = 72%; P < 0.00001) indicating a smaller change in total 25(OH)D in the vitamin D2 group compared with the vitamin D3 group.

    PMID 37865222 · one of two readings recorded this

  • Change in total 25(OH)D (weighted mean difference, LC-MS/MS studies)

    decreases, p = 0.00001

    compared with −13.77 nmol/L (95% CI: −16.75, −10.79 nmol/L; I 2 = 11%; P < 0.00001) in subjects predominantly with healthy weight

    PMID 37865222 · one of two readings recorded this

  • Change in total 25(OH)D (weighted mean difference, LC-MS/MS studies)

    no effect, p = 0.75

    MD of the vitamin D2-vitamin D3 comparison in subjects predominantly with overweight of 0.98 nmol/L (95% CI: −5.14, 7.10 nmol/L; I 2 = 0%; P = 0.75)

    PMID 37865222 · one of two readings recorded this

  • Change in total 25(OH)D (weighted mean difference)

    no effect, p = 0.05

    Excluding the studies classified as being of “high risk” of bias, the MD changed to −7.27 (95% CI: −14.67, 0.14; I 2 = 77%; P = 0.05)

    PMID 37865222 · one of two readings recorded this

  • Change in total 25(OH)D (weighted mean difference)

    decreases, p = 0.00001

    Only studies analyzed using HPLC-MS/MS | | −10.39 nmol/L | −14.62, −6.16 | <0.00001 | 64 | 293/306

    PMID 37865222 · one of two readings recorded this

The whole record — 344 rows